Digestive Diseases and Sciences

, Volume 55, Issue 5, pp 1385–1390 | Cite as

The Effect of Enteric-Coated, Delayed-Release Peppermint Oil on Irritable Bowel Syndrome

  • Shahin Merat
  • Shadi Khalili
  • Pardise Mostajabi
  • Anahita Ghorbani
  • Reza Ansari
  • Reza Malekzadeh
Original Article

Abstract

Herbal remedies, particularly peppermint, have been reported to be helpful in controlling symptoms of irritable bowel syndrome (IBS). We conducted a randomized double-blind placebo-controlled study on 90 outpatients with IBS. Subjects took one capsule of enteric-coated, delayed-release peppermint oil (Colpermin) or placebo three times daily for 8 weeks. We visited patients after the first, fourth, and eighth weeks and evaluated their symptoms and quality of life. The number of subjects free from abdominal pain or discomfort changed from 0 at week 0 to 14 at week 8 in the Colpermin group and from 0 to 6 in controls (P < 0.001). The severity of abdominal pain was also reduced significantly in the Colpermin group as compared to controls. Furthermore, Colpermin significantly improved the quality of life. There was no significant adverse reaction. Colpermin is effective and safe as a therapeutic agent in patients with IBS suffering from abdominal pain or discomfort.

Keywords

Irritable bowel syndrome Peppermint oil Delayed-action preparations Abdominal pain 

References

  1. 1.
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(2):II43–II47.PubMedGoogle Scholar
  2. 2.
    Foxx-Orenstein A. IBS–review and what’s new. MedGenMed. 2006;8:20.PubMedGoogle Scholar
  3. 3.
    Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109:1736–1741. doi:10.1016/0016-5085(95)90738-6.CrossRefPubMedGoogle Scholar
  4. 4.
    Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: Toward a cost-effective management approach. Am J Manag Care. 2001;7:S268–S275.PubMedGoogle Scholar
  5. 5.
    Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660. doi:10.1053/gast.2000.16484.CrossRefPubMedGoogle Scholar
  6. 6.
    Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17–S26.PubMedGoogle Scholar
  7. 7.
    Hadley SK, Gaarder SM. Treatment of irritable bowel syndrome. American Family Physician. 2005;72:2501–2506.PubMedGoogle Scholar
  8. 8.
    Kligler B, Chaudhary S. Peppermint oil. American Family Physician. 2007;75:1027–1030.PubMedGoogle Scholar
  9. 9.
    Gobel H, Fresenius J, Heinze A, Dworschak M, Soyka D. Effectiveness of oleum menthae piperitae and paracetamol in therapy of headache of the tension type. Nervenarzt. 1996;67:672–681. doi:10.1007/s001150050040.CrossRefPubMedGoogle Scholar
  10. 10.
    May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittel-Forschung. 1996;46:1149–1153.PubMedGoogle Scholar
  11. 11.
    Sparks MJ, O’Sullivan P, Herrington AA, Morcos SK. Does peppermint oil relieve spasm during barium enema? British Journal of Radiology. 1995;68:841–843.CrossRefPubMedGoogle Scholar
  12. 12.
    Asao T, Kuwano H, Ide M, et al. Spasmolytic effect of peppermint oil in barium during double-contrast barium enema compared with Buscopan. Clinical Radiology. 2003;58:301–305. doi:10.1016/S0009-9260(02)00532-9.CrossRefPubMedGoogle Scholar
  13. 13.
    Schuhmacher A, Reichling J, Schnitzler P. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro. Phytomedicine. 2003;10:504–510. doi:10.1078/094471103322331467.CrossRefPubMedGoogle Scholar
  14. 14.
    Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101:55–65.PubMedGoogle Scholar
  15. 15.
    Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Alimentary Pharmacology & Therapeutics. 1988;2:101–118.Google Scholar
  16. 16.
    Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi:10.1136/bmj.a2313.CrossRefPubMedGoogle Scholar
  17. 17.
    Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. BMJ. 1979;2:835–836. doi:10.1136/bmj.2.6194.835.CrossRefPubMedGoogle Scholar
  18. 18.
    Grigoleit HG, Grigoleit P. Peppermint oil in irritable bowel syndrome. Phytomedicine. 2005;12:601–606. doi:10.1016/j.phymed.2004.10.005.CrossRefPubMedGoogle Scholar
  19. 19.
    Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (mintoil) in the treatment of irritable bowel syndrome: a prospective double-blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530–536. doi:10.1016/j.dld.2007.02.006.CrossRefPubMedGoogle Scholar
  20. 20.
    Vahedi H, Merat S, Momtahen S, et al. Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2008;27:678–684.CrossRefGoogle Scholar
  21. 21.
    Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. Journal of Gastroenterology. 1997;32:765–768. doi:10.1007/BF02936952.CrossRefPubMedGoogle Scholar
  22. 22.
    Motamed N, Ayatollahi AR, Zare N, Sadeghi-Hassanabadi A. Validity and reliability of the Persian translation of the SF-36 version 2 questionnaire. East Mediterr Health J. 2005;11:349–357.PubMedGoogle Scholar
  23. 23.
    Bertram S, Kurland M, Lydick E, Locke GR 3rd, Yawn BP. The patient’s perspective of irritable bowel syndrome. Journal of Family Practice. 2001;50:521–525.PubMedGoogle Scholar
  24. 24.
    Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine. 2005;12:612–616. doi:10.1016/j.phymed.2004.10.007.CrossRefPubMedGoogle Scholar
  25. 25.
    Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterologie Clinique et Biologique. 2006;30:241–246. doi:10.1016/S0399-8320(06)73160-8.CrossRefPubMedGoogle Scholar
  26. 26.
    Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. American Journal of Gastroenterology. 2006;101:124–132. doi:10.1111/j.1572-0241.2006.00404.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Bond B, Quinlan J, Dukes GE, Mearin F, Clouse RE, Alpers DH. Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities. Clin Gastroenterol Hepatol. 2009;7:73–79. doi:10.1016/j.cgh.2008.08.011.CrossRefPubMedGoogle Scholar
  28. 28.
    Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165:1339–1341.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Shahin Merat
    • 1
  • Shadi Khalili
    • 1
  • Pardise Mostajabi
    • 1
  • Anahita Ghorbani
    • 1
  • Reza Ansari
    • 1
  • Reza Malekzadeh
    • 1
  1. 1.Digestive Disease Research Center, Shariati HospitalTehran University of Medical SciencesTehranIran

Personalised recommendations